SCYNEXIS, Inc.

    Jurisdiction
    United States
    LEI
    529900XBHFGMNTU70154
    ISIN
    US8112922005 (SCYX)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. Read full profile

    Fundamentals

    Net revenue
    €2.78M
    Gross margin
    58.1%
    EBIT
    -€31.17M
    EBIT margin
    -1,121.7%
    Net income
    -€16.65M
    Net margin
    -599.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Van Meter Stephen VP, Chief Compliance Officer -430 $50.71 -$21.81K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 158K $150.05K +8.5K Buy

    Earnings Calls

    Latest earnings call: November 9, 2022 (Q3 2022)

    Add to watchlist

    Notifications